A kind of slow-release drug stent for nasal cavity and its formation method and application

A slow-release drug and nasal cavity technology, applied in the field of medical devices, can solve the problems of untreated inflammation, unsatisfactory treatment of sinusitis and allergic rhinitis, etc., to eliminate postoperative adhesions, promote mucosal healing, and reduce mucosal inflammation and edema effect

Active Publication Date: 2022-04-01
PUYI (SHANGHAI) BIOTECHNOLOGY CO LTD
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Especially when the pit exists, the existing drug stent cannot be stretched into the pit for adhering to the wall, which will cause the inflammation to continue to develop in the pit and cannot be treated. The treatment effect of rhinitis is often not ideal

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of slow-release drug stent for nasal cavity and its formation method and application
  • A kind of slow-release drug stent for nasal cavity and its formation method and application
  • A kind of slow-release drug stent for nasal cavity and its formation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] figure 1 It is a three-dimensional schematic diagram of a sustained-release drug stent according to the first embodiment of the present invention. The sustained-release drug stent 1 includes a main body 11 and a bottom 12 that are respectively interwoven with degradable silk threads or degradable silk bundles to form a grid structure. The main body 11 extends circumferentially and has opposite ends 111 , 112 , the bottom 12 protrudes outwards in a curved shape, and the peripheral edge 121 of the bottom 12 is aligned with the edge of the end 112 . In fact, the above-mentioned main body 11 and bottom 12 are two parts artificially divided, and these two parts are not necessarily connected at the position shown in the figure. 12 drug stents are distinguished. In this embodiment, the main body 11 and the bottom 12 are integrally formed by winding in a weaving manner. Of course, it should be understood that it is also feasible to form the main body 11 and the bottom 12 sepa...

Embodiment 2

[0053] image 3 It is a three-dimensional schematic diagram of a degradable sustained-release drug stent according to the second embodiment of the present invention. The degradable sustained-release drug stent 2 also includes a main body and a bottom that are respectively interwoven with degradable silk threads or degradable silk bundles to form a grid structure , which with figure 1 Details that are the same as or similar to those of the first embodiment will not be repeated here. The difference is that the grid structure of the main body and the bottom of the drug support 2 does not include triangular structures, but only quadrilaterals 24 or polygons 25 . In this way, the drug stent 2 of this embodiment is more easily compressed and deformed to a smaller shape, which facilitates the delivery of the stent to a narrower space. In particular, the drug stent 2 is suitable for the middle meatus, the upper meatus, the lower meatus, etc., and can also be placed inside sinuses su...

Embodiment 3

[0055] Figure 4 It is a three-dimensional schematic diagram of a degradable sustained-release drug stent according to the third embodiment of the present invention. The degradable sustained-release drug stent 3 also includes a main body and a bottom that are respectively interwoven with degradable silk threads or degradable silk bundles to form a grid structure , wherein, the grid structure at the bottom includes a triangular structure 33 to ensure the support force and dimensional stability of the stent, and is suitable for implantation in parts with large openings. The grid structure of the main body includes a quadrilateral structure 34 to facilitate the delivery of the stent to the nasal cavity. other with figure 1 The same or similar specific details of the first embodiment will not be repeated here. The difference is that the main body of the drug stent 3 in this embodiment has less material, which ensures more support while minimizing the reduction in the support perfo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a slow-release drug stent for nasal cavity, which comprises a main body and at least one bottom formed by interweaving silk threads or silk bundles with each other to form a grid structure, the main body extends circumferentially and has ends opposite to each other, and the bottom The curved surface protrudes outwards, the periphery of the bottom is aligned with the edge of the end, and the main body and the bottom are loaded with slow-release medicine for treating sinusitis. The invention also provides a method for forming the sustained-release drug stent used in the nasal cavity. The slow-release drug stent for nasal cavity provided by the present invention uses the wall of the main body to carry out adhering treatment on the wound surface, and at the same time uses the bottom to extend into the pit of the diseased part for adhering treatment, thereby acting on the inflammation in the pit and effectively reducing Mucosal inflammation and edema, promote mucosal healing, reduce scar formation, and eliminate postoperative adhesions.

Description

technical field [0001] The invention relates to a medical device, in particular to a slow-release drug support for nasal cavity and its forming method and application. Background technique [0002] Sinusitis and allergic rhinitis are common and frequently-occurring diseases of ENT, which occur between the ages of 5 and 79. According to the survey of the health department: the current global incidence of allergic rhinitis is as high as 10% to 14%, and the incidence of sinusitis accounts for about 15% of the population. Nearly 600 million people in the world are suffering from rhinitis, and it is gradually increasing. Upward trend. [0003] 66% of asthma patients are victims of allergic rhinitis. According to experts, if allergic rhinitis is not properly treated, more than one-third of patients will eventually develop asthma. [0004] In addition, 30% of the incidence of anosmia is caused by chronic sinusitis, resulting in respiratory hyposmia or anosmia. Produced by the c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61F2/90A61M31/00
Inventor 谢建魏征晏伟
Owner PUYI (SHANGHAI) BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap